Recent progress on formulations of hirudin
Pharmaceutical Science Advances · 2025-12 · 3 · 100078
DOI: 10.1016/j.pscia.2025.100078 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutical Science Advances, 2025-12. Verfasst von Zheng Bao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Collaborative Innovation Centre of Chinese Medicinal Resources Industrialization, National and Local Collaborative Engineering Centre of Chin…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Jiangsu Province, National College Students Innovation and Entrepreneurship Training Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Hirudin is an effective active ingredient derived from the salivary glands of leech. It is a small peptide molecule consisting of 65-66 amino acids and demonstrates a strong inhibitory effect on thrombin, providing beneficial anticoagulant and antithrombotic properties. However, as a biopharmaceutical peptide, it has some drawbacks such as easy degradation, short half-life, low bioavailability, and high risk of hemorrhage in clinical use. To overcome these challenges, various formulations were developed. In this work, a comprehensive review of research progress was provided in both traditional and novel hirudin formulations, spanning from lyophilized powders to biotechnology-based pharmaceuticals, covering various dosage forms to offer comprehensive references for field research. Firstly the advantages and limitations of conventional preparations were assessed such as freeze-dried powders, capsules, and injections. Then a detailed exploration of frontier strategies including nanotechnology-based delivery systems, transdermal formulations, and biotechnology-driven prodrug designs were conducted. This article aims to comprehensively analyze cutting-edge advancements in hirudin preparation research, providing updated information for relevant researchers by integrating traditional dosage optimization with breakthrough emerging technologies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangsu Collaborative Innovation Centre of Chinese Medicinal Resources Industrialization, National and Local Collaborative Engineering Centre of Chinese Medicinal Resources Industrialization and Formulae Innovative Medi…
- Nanjing University of Chinese Medicine Hanlin College, Taizhou, 225300, China.
Förderung
- Natural Science Foundation of Jiangsu Province
- National College Students Innovation and Entrepreneurship Training Program
- National Natural Science Foundation of China
Zitieren
APA
Bao, Z., Qi, X., Zhu, S., Zhang, M., Liu, X., Chen, P., Zhang, L., Geng, T., & Cheng, F. F. (2025). Recent progress on formulations of hirudin. Pharmaceutical Science Advances, 3, 100078. https://doi.org/10.1016/j.pscia.2025.100078
Vancouver
Bao Z, Qi X, Zhu S, Zhang M, Liu X, Chen P, et al. Recent progress on formulations of hirudin. Pharmaceutical Science Advances. 2025;3:100078. doi:10.1016/j.pscia.2025.100078
BibTeX
@article{Bao2025,
author = {Bao, Zheng and Qi, Xingyu and Zhu, Suling and Zhang, Mao and Liu, Xinyue and Chen, Peidong and Zhang, Li and Geng, Ting and Cheng, Fang-Fang},
title = {Recent progress on formulations of hirudin},
journal = {Pharmaceutical Science Advances},
year = {2025},
volume = {3},
pages = {100078},
doi = {10.1016/j.pscia.2025.100078}
}
EUVIMED